GR3023070T3 - NOVEL HYBRID, SOLUBLE AND UNCLEAVED gp160 VARIANT - Google Patents

NOVEL HYBRID, SOLUBLE AND UNCLEAVED gp160 VARIANT

Info

Publication number
GR3023070T3
GR3023070T3 GR970400738T GR970400738T GR3023070T3 GR 3023070 T3 GR3023070 T3 GR 3023070T3 GR 970400738 T GR970400738 T GR 970400738T GR 970400738 T GR970400738 T GR 970400738T GR 3023070 T3 GR3023070 T3 GR 3023070T3
Authority
GR
Greece
Prior art keywords
hiv
region
strain
soluble
derived
Prior art date
Application number
GR970400738T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of GR3023070T3 publication Critical patent/GR3023070T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
GR970400738T 1991-05-02 1997-04-08 NOVEL HYBRID, SOLUBLE AND UNCLEAVED gp160 VARIANT GR3023070T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR919105392A FR2676071B1 (fr) 1991-05-02 1991-05-02 Nouveau variant gp160 non-clivable, soluble, de forme hybride.
PCT/FR1992/000394 WO1992019742A1 (fr) 1991-05-02 1992-04-30 NOUVEAU VARIANT gp160 NON-CLIVABLE, SOLUBLE, DE FORME HYBRIDE

Publications (1)

Publication Number Publication Date
GR3023070T3 true GR3023070T3 (en) 1997-07-30

Family

ID=9412448

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970400738T GR3023070T3 (en) 1991-05-02 1997-04-08 NOVEL HYBRID, SOLUBLE AND UNCLEAVED gp160 VARIANT

Country Status (12)

Country Link
US (2) US6261799B1 (el)
EP (1) EP0541753B1 (el)
JP (1) JP3453611B2 (el)
AT (1) ATE149203T1 (el)
CA (1) CA2086509C (el)
DE (1) DE69217614T2 (el)
DK (1) DK0541753T3 (el)
ES (1) ES2099257T3 (el)
FR (1) FR2676071B1 (el)
GR (1) GR3023070T3 (el)
SG (1) SG44828A1 (el)
WO (1) WO1992019742A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677225B2 (en) * 1992-10-06 1997-04-17 Dade Behring Marburg Gmbh Retrovirus from the HIV group and its use
JP3658690B2 (ja) * 1993-01-16 2005-06-08 マンフレート シャヴァラー ウイルスの膜蛋白質の天然ドメインの獲得方法、特にｈｉｖに対するワクチンとしてのそれらの使用
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
NZ520754A (en) 2000-02-10 2004-02-27 Panacos Pharmaceuticals Inc Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
KR102007444B1 (ko) * 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
JP2015522580A (ja) * 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
UY37975A (es) * 2017-11-17 2019-02-28 Grifols Diagnostic Solutions Inc Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
EP0272858A3 (en) * 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
JP3494300B2 (ja) * 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Ｈｉｖに対する予防接種のための方法および組成物

Also Published As

Publication number Publication date
DK0541753T3 (da) 1997-08-04
FR2676071A1 (fr) 1992-11-06
EP0541753A1 (fr) 1993-05-19
CA2086509C (fr) 2003-07-01
FR2676071B1 (fr) 1994-11-18
CA2086509A1 (fr) 1992-11-03
US6284248B1 (en) 2001-09-04
ES2099257T3 (es) 1997-05-16
SG44828A1 (en) 1997-12-19
EP0541753B1 (fr) 1997-02-26
WO1992019742A1 (fr) 1992-11-12
JP3453611B2 (ja) 2003-10-06
US6261799B1 (en) 2001-07-17
ATE149203T1 (de) 1997-03-15
DE69217614T2 (de) 1997-07-10
DE69217614D1 (de) 1997-04-03
JPH05508324A (ja) 1993-11-25

Similar Documents

Publication Publication Date Title
DE60037450D1 (de) Funf-helix protein
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
LU91166I2 (fr) Enfuvirtide, facultativement sous forme d'un sel ou ester pharmaceutiquement acceptable (FUZEON).
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
EP0651818A4 (en) IMMUNOGENIC PEPTIDES, ANTIBODIES AND USES THEREOF IN CONNECTION WITH THE BINDING OF THE CD4 MOLECULE RECEPTOR.
DE69534569D1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
EP0815125A4 (en) gC1q RECEPTOR, BINDING HIV-1 gp120 REGION, RELATED PEPTIDES AND ANTIBODIES
WO1991009872A3 (en) Hiv-1 env fragment fusion protein
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
GR3023070T3 (en) NOVEL HYBRID, SOLUBLE AND UNCLEAVED gp160 VARIANT
CA2131153A1 (en) Peptides stimulating cytotoxic lymphocytes response to hiv-i gp 160
EP0255190A3 (en) Recombinant polypeptides and their uses, inclusing assay for aids virus
ATE199394T1 (de) Gag-env fusion-antigen aus hiv
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
AU651113B2 (en) HIV GP120 monoclonal antibodies
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.
Ivanoff et al. Human immunodeficiency virus antigen.